Search for:
  • Sign in
  • Register
  • Reports
  • Interviews
  • Articles
  • Legal & Regulatory
  • Facts & Figures
  • Op-eds
  • Shop
Friday, November 6, 2026
PharmaBoardroom
Sign In Register
  • Home
  • Country Reports
    • All
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Exclusive interviews
    • All
    • Latest
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Articles
    • All
    • Global
    • Latest
  • Legal & Regulatory
    • All
    • The Pharma Legal Handbook
    • Regulatory, Pricing and Reimbursement
    • Marketing, Manufacturing, Packaging and Labeling
    • Preclinical and Clinical Trials
  • Op-Eds & Contributions
  • InFigures
    • All
    • Rankings
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Library
    • All
    • InFocus
    • InFigures
    • White Papers
  • Media Kit
  • Register
  • About Us
  • Reports
  • Interviews
  • Articles
  • Legal & Regulatory
  • Facts & Figures
  • Op-eds
  • Shop
Turkey: Pharma Market Report 2015 Download

Turkey

October 2012

See more

Key Market Facts

  • Turkey's pharmaceutical market was valued at approximately TRY 18-20 billion ($6.5-7.5 billion) in 2015, with rapid growth driven by a large and young population, expanding health insurance coverage, and rising chronic disease rates.
  • Abdi Ibrahim, Eczacibasi, Deva Holding, Santa Farma, and Nobel Ilac are among Turkey's major domestic pharmaceutical manufacturers, with the industry employing over 20,000 people and exporting to more than 100 countries.
  • Regulatory authority: TITCK (Turkish Medicines and Medical Devices Agency) governs pharmaceutical regulation in Turkey, having undergone significant modernisation to align with EU regulatory standards as part of Turkey's EU accession process.
  • Turkey's pharmaceutical sector has developed a strong generics manufacturing base, producing approximately 60-65% of domestic pharmaceutical needs locally by volume, supported by government incentives for local production.
  • Currency depreciation and government drug price controls have been persistent challenges for Turkey's pharmaceutical market since 2011, with ongoing reductions in the exchange rate reference used for pricing eroding manufacturer revenues.

Legal & Regulatory

report
Buy
Share on Linkedin Share

Sharing Link

or sharing via

WhatsApp Email
Back
PharmaBoardroom

PharmaBoardroom Limited
Evolution House
Iceni Court, Delft Way,
Norwich, NR6 6BB UK

Latest

  • Articles
  • In Conversation
  • Facts & Figures
  • Country Reports
  • Legal & Regulatory
  • InFocus

More

  • About Us
  • Media Kit

Join Us

  • Email Newsletters
  • LinkedIn

Contact

+44 0 207 870 3438

info@pharmaboardroom.com

Legal & Privacy

  • Terms and Conditions
  • Privacy and Cookies policy
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here

logo

Sign in

Forgot password? Register now